Impact of genetic polymorphisms of drug transporters
ABCB1
ABCG2
CAR
Chronic myeloid leukemia
PXR
dasatinib
single nucleotide polymorphisms
Journal
Frontiers in oncology
ISSN: 2234-943X
Titre abrégé: Front Oncol
Pays: Switzerland
ID NLM: 101568867
Informations de publication
Date de publication:
2022
2022
Historique:
received:
25
05
2022
accepted:
11
08
2022
entrez:
10
10
2022
pubmed:
11
10
2022
medline:
11
10
2022
Statut:
epublish
Résumé
Functional single-nucleotide polymorphisms (SNPs) in genes regulating cellular uptake, elimination, and metabolism of xenobiotics may potentially influence the outcome of chronic myeloid leukemia (CML) patients treated with BCR-ABL1 tyrosine kinase inhibitors (TKI). Dasatinib, a second-generation TKI, is a substrate of the ABC-superfamily xenobiotic transporters ABCB1 (MDR1, Pg-P) and ABCG2 (BCRP). Pregnane X receptor (PXR, NR1I2) and constitutive androstane receptor (CAR, NR1I3) are involved in the control of expression of In this study, we assessed the impact of inherited variants in Sixty-one tagging SNPs in We found the associations between SNPs rs7787082 ( Our data suggest that inherited variants in the genes encoding for proteins involved in the transport of xenobiotics may modify the toxicity and efficacy of dasatinib therapy in CML patients.
Identifiants
pubmed: 36212403
doi: 10.3389/fonc.2022.952640
pmc: PMC9537611
doi:
Types de publication
Journal Article
Langues
eng
Pagination
952640Informations de copyright
Copyright © 2022 Madejczyk, Canzian, Góra-Tybor, Campa, Sacha, Link-Lenczowska, Florek, Prejzner, Całbecka, Rymko, Dudziński, Orzechowska and Jamroziak.
Déclaration de conflit d'intérêts
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Références
Semin Liver Dis. 2002;22(2):115-22
pubmed: 12016543
Leukemia. 2020 Apr;34(4):966-984
pubmed: 32127639
Nat Med. 2001 May;7(5):584-90
pubmed: 11329060
Mol Pharmacol. 2002 Sep;62(3):638-46
pubmed: 12181440
Nature. 1973 Jun 1;243(5405):290-3
pubmed: 4126434
Cancer Chemother Pharmacol. 2008 Mar;61(3):365-76
pubmed: 17429625
Biochim Biophys Acta. 2005 Dec 30;1754(1-2):3-13
pubmed: 16172030
Pharmacogenomics. 2008 Jan;9(1):105-27
pubmed: 18154452
Blood. 2009 Dec 3;114(24):4944-53
pubmed: 19779040
J Biol Chem. 2002 Jan 25;277(4):2908-15
pubmed: 11706036
Pharmacogenet Genomics. 2014 Jan;24(1):52-61
pubmed: 24322003
Nat Med. 1996 May;2(5):561-6
pubmed: 8616716
J Clin Pharm Ther. 2015 Dec;40(6):680-4
pubmed: 26417664
J Med Chem. 2004 Dec 30;47(27):6658-61
pubmed: 15615512
J Cardiovasc Pharmacol Ther. 2015 Nov;20(6):532-8
pubmed: 25848132
Ann Oncol. 2013 Mar;24(3):756-60
pubmed: 23117072
Hematol Oncol Clin North Am. 2004 Jun;18(3):641-56, ix
pubmed: 15271397
J Biol Chem. 2001 May 4;276(18):14581-7
pubmed: 11297522
Int J Cancer. 2012 Dec 15;131(12):2920-8
pubmed: 22473764
Leukemia. 2003 Dec;17(12):2318-57
pubmed: 14562125
Clin Cancer Res. 2009 Jul 15;15(14):4750-8
pubmed: 19584153
Annu Rev Pharmacol Toxicol. 2001;41:123-43
pubmed: 11264453
Front Oncol. 2021 May 13;11:672287
pubmed: 34055641
Clin Ther. 2008 Nov;30(11):1956-75
pubmed: 19108785
J Hum Genet. 2010 Nov;55(11):731-7
pubmed: 20720558
J Natl Cancer Inst. 1960 Jul;25:85-109
pubmed: 14427847